Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Total Product Sales by Quarter
Total Product Sales — Worldwide net selling price change YoY (%) (%)
Amgen Total Product Sales: -2.0% in Q1 2026, up 4.0 pts from a year earlier.
Latest, Q1 2026
-2.0%
Period ended Mar 31, 2026
Change on a year earlier
+4.0 pts
-6.0% in Q1 2025
History
3 quarters
Since Q4 2023
Sources
3
Documents cited below
Where the Q1 2026 figure comes from
“Total product sales increased 4% for the three months ended March 31, 2026, driven by volume growth of 9%, partially offset by declines in net selling price of 2% and 2% from lower wholesaler and end user inventory.”
Source: Form 10-Q (amgn-20260331.htm, filed 2026-05-01) ↗
Reported in Form 8-K Key Results & Form 10-Q / 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Product Sales — Worldwide net selling price change YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | -2.0% | +4.0 pts | Form 10-Q (amgn-20260331.htm, filed 2026-05-01) ↗ |
| Q1 2025 | Mar 31, 2025 | -6.0% | – | Form 10-Q (amgn-20250331.htm, filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | -3.0% | – | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
Cite this data
StockData. (2026). Amgen Total Product Sales (%), quarterly Q4 2023–Q1 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-total-price
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.